ELi Lilly Presents Data on Cixutumumab in Five Subtypes of Sarcoma

Eli Lilly and Company LLY announced data from its Phase II study with cixutumumab in five subtypes of sarcoma, a cancer that develops from connective tissues in the body. Study results demonstrated that 57 percent of patients with a soft tissue sarcoma known as adipocytic sarcoma experienced stable disease. Results from the Phase II study will be presented on Monday, June 6 at 4:15 p.m. CDT during the Sarcoma Oral Abstract Session at the 47th Annual Meeting of the American Society of Clinical Oncology in Chicago, Ill.